A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders.
Phase of Trial: Phase II
Latest Information Update: 29 May 2012
At a glance
- Drugs CTS 1027; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Oct 2011 Status changed from active, no longer recruiting to discontinued.
- 03 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2011 Additional lead trial investigators identified as reported by ClinicalTrials.gov.